Concepedia

Mary Varterasian

MV

29

Publications

3.1K

Citations

22

H-Index

1992

Active since

Affiliations

Wayne State University(Current)

The Barbara Ann Karmanos Cancer Institute

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

Mayo Clinic in Arizona

Mary Varterasian is an author at Wayne State University specializing in medicine, oncology, and immunology.

ORCID

Top concepts

Publications per year

1992–2023

29

Publications

29

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

John J. Rinehart, Alex A. Adjei, Patricia LoRusso et al. · Journal of Clinical Oncology · 2004 · 635 citations

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Ryan J. Sullivan, Jeffrey R. Infante, Filip Jankú et al. · Cancer Discovery · 2017 · 401 citations

Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies

Patricia LoRusso, Alex A. Adjei, Mary Varterasian et al. · Journal of Clinical Oncology · 2005 · 397 citations

Intratumoral injection of <i>Clostridium novyi</i> -NT spores induces antitumor responses

Nicholas J. Roberts, Linping Zhang, Filip Jankú et al. · Science Translational Medicine · 2014 · 368 citations · Full text

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

Oday Hamid, Mary Varterasian, Scott Wadler et al. · Journal of Clinical Oncology · 2003 · 144 citations

Rows per page

1–5 of 29